A randomized controlled study of floating acupuncture in treating dysmenorrhea of adenomyosis with kidney qi deficiency and blood stastics

注册号:

Registration number:

ITMCTR2200005504

最近更新日期:

Date of Last Refreshed on:

2022-01-05

注册时间:

Date of Registration:

2022-01-05

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

浮针治疗肾虚血瘀型子宫腺肌病痛经的随机对照研究

Public title:

A randomized controlled study of floating acupuncture in treating dysmenorrhea of adenomyosis with kidney qi deficiency and blood stastics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

浮针治疗子宫腺肌病痛经的单中心、随机对照研究

Scientific title:

A single-center, randomized controlled study of Fu's subacupuncture in the treatment of dysmenorrhea in adenomyosis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200055295 ; ChiMCTR2200005504

申请注册联系人:

黄辉霞

研究负责人:

黄辉霞

Applicant:

Huixia,Huang

Study leader:

Huixia,Huang

申请注册联系人电话:

Applicant telephone:

13922176391

研究负责人电话:

Study leader's telephone:

13922176391

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

81924406@qq.com

研究负责人电子邮件:

Study leader's E-mail:

81924406@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州市白云区机场路16号1号楼9楼

研究负责人通讯地址:

广州市白云区机场路16号1号楼9楼

Applicant address:

9 / F, building 1, No. 16, Airport Road, Baiyun District, Guangzhou

Study leader's address:

9 / F, building 1, No. 16, Airport Road, Baiyun District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Guangzhou University of chinese mideicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

NO.K[2021]041

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广州中医药大学第一附属医院伦理委员会

Name of the ethic committee:

The First Affiliated Hospital of Guangzhou University of chinese mideicine ehic committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021/6/10 0:00:00

伦理委员会联系人:

黎欣盈

Contact Name of the ethic committee:

Xinying,LI

伦理委员会联系地址:

广州中医药大学第一附属医院大学针推楼501伦理委员会

Contact Address of the ethic committee:

The First Affiliated Hospital of Guangzhou University of chinese mideicine ehic committee

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-36591965

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gztcmlunli@163.com

研究实施负责(组长)单位:

广州中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Guangzhou University of chinese mideicine

研究实施负责(组长)单位地址:

广州市白云区机场路16号

Primary sponsor's address:

No. 16, Airport Road, Baiyun District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第一附属医院

具体地址:

广州市白云区机场路16号

Institution
hospital:

The First Affiliated Hospital of Guangzhou University of chinese mideicine

Address:

No. 16, Airport Road, Baiyun District, Guangzhou

经费或物资来源:

广东中医针灸重点实验室开放课题

Source(s) of funding:

Guangdong Key Laboratory of traditional Chinese medicine and acupuncture

研究疾病:

子宫腺肌病痛经

研究疾病代码:

Target disease:

dysmenorrhea in adenomyosis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

1、验证浮针治疗 AM 痛经的安全性、有效性; 2、探讨浮针治疗与散结镇痛胶囊治疗AM痛经的疗效对比; 3、探讨浮针治疗对经阴道彩超子宫声像图及子宫血流动力的影响,挖掘浮针治疗AM痛经影响子宫血液循环的证据

Objectives of Study:

1. Verify the safety and effectiveness of FU's Subaccupunture in the treatment of AM dysmenorrhea; 2. To explore the comparison of the curative effect of FU's SubaccupuntureTreatment and Sanjiezhongcapsules in the treatment of AM dysmenorrhea; 3. To explore the effect of FU's Subaccupunturetherapy on transvaginal color ultrasound uterine sonograms and uterine hemodynamics, and to explore the evidence of the effect of FU's Subaccupunturetherapy on AM dysmenorrhea on uterine blood circulation

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合AM诊断标准;②以痛经为主诉;③疼痛VAS评分4-10分;④年龄介于20岁至49岁之间;⑤中医辨证属于肾虚血瘀证;⑥自愿签署知情同意书者。

Inclusion criteria

① Meet the AM diagnostic criteria; ② Dysmenorrhea was the chief complaint; ③ VAS score of pain was 4-10; ④ between the ages of 20 and 49; (5) TCM syndrome differentiation belongs to kidney deficiency and blood stasis syndrome; ⑥ Voluntary signing of the informed consent.

排除标准:

①正在服用避孕药、使用宫内节育器、半年内计划妊娠、妊娠期或哺乳期的患者;②过敏体质患者;③血液系统疾病患者;④肝、肾功能明显异常(即指标高于正常值一倍以上);⑤脑部或精神疾病,判定能力异常;⑥药物及或酒精滥用;⑦有子宫肌瘤、子宫腺肌瘤、卵巢占位,且肿物直径>4cm或符合其他手术指征者;⑧近3月内服用避孕药或其它含有激素类药物者;⑨黏膜下肌瘤;⑩无性生活。

Exclusion criteria:

1) Patients who are taking contraceptives, using IUDs, planning pregnancy, pregnancy or lactation within half a year; ② patients with allergic constitution; ③ patients with diseases of the blood system; (4) liver and kidney function was significantly abnormal (that is, the index was more than one time higher than the normal value); (5) brain or mental illness, abnormal judgment ability; ⑥ Drug and/or alcohol abuse; 7. Patients with uterine fibroids, adenomyomas, ovarian mass, and tumor diameter >4cm or other surgical indications; (8) People who have taken contraceptives or other hormone-containing drugs within the last 3 months; ⑨ Submucosal fibroids; Attending non-sexual life.

研究实施时间:

Study execute time:

From 2022-03-01

To      2023-09-01

征募观察对象时间:

Recruiting time:

From 2022-03-01

To      2023-09-01

干预措施:

Interventions:

组别:

浮针治疗

样本量:

59

Group:

FU‘s subaccupunture

Sample size:

干预措施:

口服散结镇痛胶囊

干预措施代码:

001

Intervention:

Oral Sanjie Analgesic Capsules

Intervention code:

样本总量 Total sample size : 118

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第一附属医院

单位级别:

综合医院三级甲等

Institution/hospital:

The First Affiliated Hospital of Guangzhou University of chinese mideicine

Level of the institution:

General Hospital Grade 3, Grade A

测量指标:

Outcomes:

指标中文名:

经阴道子宫彩超声像图

指标类型:

次要指标

Outcome:

Transvaginal uterine color ultrasound image

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

COX痛经症状量表

指标类型:

主要指标

Outcome:

The?Cox?Menstrual?Symptom?Scale,?CMSS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾虚血瘀证症状积分

指标类型:

次要指标

Outcome:

TCM Symptom Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CA125

指标类型:

次要指标

Outcome:

ca125

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子宫动脉血流动力

指标类型:

次要指标

Outcome:

Uterine arterial hemodynamics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

布洛芬使用情况

指标类型:

次要指标

Outcome:

Ibuprofen usage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清PGF2a

指标类型:

次要指标

Outcome:

PGF2a

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血浆

组织:

血液

Sample Name:

The plasma

Tissue:

blood

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

具体方法:①用PEMS3.1统计软件产生随机数字,制成RP随机分配卡;②将卡片装入依次编号的不透明信封(信封的编号与卡片上的序号相同);③按照进入试验的顺序依照信封编号拆封取卡;④严格按卡片序号规定分为浮针治疗组、口服散结镇痛胶囊组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Specific methods: ① Use PEMS3.1 statistical software to generate random numbers and make RP random distribution card; ② Put the cards into an opaque envelope with serial numbers (the envelope number is the same as the serial number on the card); (3) Unseal and take out the card according to the

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年6月,中国临床实验注册中心,http://www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

In June 2023, China clinical trial registration center,http://www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above